Evidence map›Paper›PMID 33028228›Full record

ArticleBMC infectious diseases2020

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach.

Wei Li, Te-Sheng Chang, Shu-Zhi Chang, Ching-Hwa Chen, Mei-Yen Chen

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wei LiFormosa Plastics Group Health Care, Yunlin, Taiwan.
Te-Sheng ChangDepartment of Internal Medicine, Division of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Yunlin, Taiwan.
Shu-Zhi ChangFormosa Plastics Group Health Care, Yunlin, Taiwan.
Ching-Hwa ChenFormosa Plastics Group, Advanced Engineer, Safety Health and Environment Center, Taipei, Taiwan.
Mei-Yen ChenDepartment of Nursing, Chang Gung University of Science and Technology, Chiayi, Taiwan. meiyen@mail.cgust.edu.tw.ORCID http://orcid.org/0000-0002-8980-1300
Formosa Plastics (Taiwan) · TWChang Gung Memorial Hospital · TWChang Gung University of Science and Technology · TW

Funding

Chang Gung Memorial Hospital, Linkou bmrp148
6 · The paper itself

Abstract

backgroundChronic hepatitis C virus (HCV), which is a concern in many countries, is the leading cause of liver cancer around the world. Since Taiwan launched its national health insurance system in 1995, it has managed to extend health coverage to 99% of the Taiwanese population, providing free but limited antiviral treatment each year since 2017. However, many people in rural areas are unaware that they have chronic HCV; nor do they realize that new drugs with high cure rates could drastically reduce their health burden. The aim of this study is to explore the implementation facilitators of and barriers to inviting potentially infected patients in rural areas to be transferred for HCV ribonucleic acid (RNA) confirmation and new drug treatment.

methodsA descriptive and prospective study design with an interdisciplinary collaboration approach was implemented. After five elements of referral were developed, telephone counseling was conducted between August 2018 and May 2019 in Yunlin, Taiwan. The elements of referral developed by the research team were: (1) forming and coordinating physicians' schedules, (2) recruiting and training volunteers, (3) training the nursing staff, (4) raising funds or resources, and (5) connecting with village leaders. Thereafter, we collaborated with two district health centers, a private local hospital, and health clinics. Based on the medical records provided by these agencies, community adults that were HCV antibody (anti-HCV) positive were invited to join the program.

resultsOf the 1795 adults who were serum anti-HCV positive, 1149 (64%) accepted transfer to a qualified hospital; of these, 623 (54.2%) had an HCV infection. 552 (88.6%) of those infected started receiving direct-acting antivirals (DAAs) treatment. The top four barriers to accepting transfer were: (1) they perceived themselves to be healthy (n = 98, 32.3%); (2) mistrust of treatment/healthcare (n = 60, 20.2%); (3) limited transportation to the hospital (n = 52, 17.5%); and (4) work conflict (n = 30, 10.1%).

conclusionAn interdisciplinary collaboration approach significantly contributed to the invitation of CHC patients, as well as their acceptance of HCV RNA confirmation and free DAAs treatment. Using anti-HCV data from previous medical records for case-finding and collaborating with a hospital and health clinics proved to be an efficient strategy.

Indexed as

AdultAntiviral AgentsFemaleHepacivirusHepatitis C AntibodiesHepatitis C, ChronicHumansInterdisciplinary CommunicationInterviews as TopicMaleMiddle AgedProspective StudiesReferral and ConsultationRNA, ViralRural PopulationTaiwanAntiviral AgentsHepatitis C AntibodiesRNA, ViralAnti-HCV positiveBarriersDirect-acting antiviralsFacilitatorsHepatitis C eliminationRural

Identifiers

PMID33028228
PMCPMC7542903
OpenAlexW3091768758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.